162 related articles for article (PubMed ID: 4790261)
21. [Reduced glutathione and enzyme activities in erythrocytes of various again myeloproliferative diseases].
Benöhr HC; Kraft R; Waller HD
Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1592-5. PubMed ID: 1030056
[No Abstract] [Full Text] [Related]
22. Phagocytosis in myeloproliferative disorders.
Corberand J; LaHarrague P; De Larrard B; Nguyen F; Pris J
Am J Clin Pathol; 1980 Sep; 74(3):301-5. PubMed ID: 6932175
[TBL] [Abstract][Full Text] [Related]
23. [On the existence of a myeloproliferative factor in patients with a myeloproliferative syndrome (author's transl)].
Essers U; Nowak H
Blut; 1979 Aug; 39(2):107-15. PubMed ID: 289427
[TBL] [Abstract][Full Text] [Related]
24. Stainable blood platelet glycogen in various conditions.
Hermanský F; Hrodek O; Matousová O; Cieslar P
Acta Univ Carol Med Monogr; 1972; 53():165-71. PubMed ID: 4598518
[No Abstract] [Full Text] [Related]
25. Platelet defects in the myeloproliferative disorders.
Inceman S; Tangün Y
Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
[No Abstract] [Full Text] [Related]
26. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
27. Levels in normal, pathological, and foetal sera of the three transcobalamins.
Bloomfield FJ; Scott JM; Somerville JJ; Weir DG
Ir J Med Sci; 1973 Mar; 142(2):51-7. PubMed ID: 4527886
[No Abstract] [Full Text] [Related]
28. [Metamorphosis of chronic myeloproliferative diseases].
Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716
[No Abstract] [Full Text] [Related]
29. [The total and isoenzyme-lactate dehydrogenase content of plasma, leukocytes and erythrocytes in myeloproliferative diseases].
Helbig W; Parthum K; Sommer HJ
Folia Haematol Int Mag Klin Morphol Blutforsch; 1971; 95(3):229-37. PubMed ID: 4106013
[No Abstract] [Full Text] [Related]
30. Progenitor cell trafficking in physiologic conditions and in myeloproliferative diseases: quantification of CD34+ cells by polymerase chain reaction.
Oppliger Leibundgut E; Brunold C; Marti D; Horn MP; Seiler C; Schroeder V; Schmid JP; Tobler A; Zwicky C
Haematologica; 2005 Jul; 90(7):875-80. PubMed ID: 15996924
[TBL] [Abstract][Full Text] [Related]
31. Studies on the phagocytic activity of neutrophilic leukocytes.
Brandt L
Scand J Haematol Suppl; 1967; 2():1-126. PubMed ID: 5243720
[No Abstract] [Full Text] [Related]
32. [Characteristics of the morphology and function of the thrombocytes in myeloproliferative diseases].
Petrov MN; Vashkinel' VK
Probl Gematol Pereliv Krovi; 1977 May; 22(5):18-23. PubMed ID: 267283
[No Abstract] [Full Text] [Related]
33. Megakaryocytes in cubital venous blood in patients with chronic myeloproliferative diseases.
Tinggaard Pedersen N; Laursen B
Scand J Haematol; 1983 Jan; 30(1):50-8. PubMed ID: 6573016
[TBL] [Abstract][Full Text] [Related]
34. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
[TBL] [Abstract][Full Text] [Related]
36. [Radioimmunometric determination of histamine in myeloproliferative syndromes].
Bettelheim P; Valent P
Wien Klin Wochenschr; 1989 Oct; 101(20):706-10. PubMed ID: 2480027
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic evaluation of the chronic myeloproliferative disorders.
Spivak JL
Isr Med Assoc J; 2002 Nov; 4(11):1028-31. PubMed ID: 12489498
[No Abstract] [Full Text] [Related]
38. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
39. [Cytometric characteristics of erythrocytes in polycythemia vera].
Kotsiubinskiĭ NN; Dygin VP; Koval' IuV
Probl Gematol Pereliv Krovi; 1982 Mar; 27(3):33-6. PubMed ID: 7045861
[No Abstract] [Full Text] [Related]
40. [Glycosaminoglycans of human thrombocytes in normal conditions, in chronic myeloid leukosis, myelofibrosis and polycythemia vera].
Kharchenko MF
Vopr Med Khim; 1973; 19(6):613-7. PubMed ID: 4277844
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
